Select Biosciences Ltd

News Headlines

Scientists Kill Cancer Cells With "Trojan Horse"
02 July 2009
New therapy combats cancer, using a bacterially-derived nano cell to penetrate and disarm the cancer cell before a second nano cell kills it with chemotherapy drugs.

Cenix BioScience Expands Relationship with AstraZeneca, Signing Multi-Project Research Agreement
26 June 2009
The new agreement calls for Cenix to complete three major projects applying same platform for RNAi-based research.

Exosome Diagnostics and DxS Collaborate to Develop Blood Based Tests for Key Cancer Mutations
26 June 2009
The collaboration is based on the development of blood based companion diagnostics for key cancer gene mutations.

MDRNA Gains Full Financial and Transactional Control of Its Proprietary UNA Technology
23 June 2009
Company amends agreement with RiboTask to eliminate all milestone and royalty payments.

Tuning Silica Nanoparticles for Cell Specific Biotargeting
22 June 2009
Using Malvern’s Zetasizer Nano, researchers showed that poly (ethylene imine) functionalized silica particles make promising candidates for bioapplications.

Alnylam and Collaborators Present Pre-Clinical Research Findings on RNAi Therapeutics Targeting PCSK9
19 June 2009
New data include use of novel lipid nanoparticles with improved potency, achieving a new benchmark for systemically delivered RNAi therapeutics.

New Research Highlights Potential of Novel Alpha-Pharmaceutical in Targeting and Killing Breast Cancer Cells
19 June 2009
Targeted anticancer effect of alpha-emitter linked to Herceptin presented at Society of Nuclear Medicine meeting.

New Strategy Reveals Targets for MicroRNA Gene Regulation
19 June 2009
Researchers use HITS-CLIP technique to map the binding points of scores of different microRNAs throughout a genome in living mouse or human tissue.